The RD1-encoded antigen Rv3872 of Mycobacterium tuberculosis as a potential candidate for serodiagnosis of tuberculosis  by Mukherjee, P. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01660.x
The RD1-encoded antigen Rv3872 of Mycobacterium tuberculosis as a
potential candidate for serodiagnosis of tuberculosis
P. Mukherjee1, M. Dutta1, P. Datta1, A. Dasgupta1, R. Pradhan2, M. Pradhan2, M. Kundu1, J. Basu1 and
P. Chakrabarti1
1Department of Chemistry, Bose Institute and 2Bengal Tuberculosis Association, Kolkata, India
ABSTRACT
Tuberculosis (TB) infections in India account for one-third of the global burden, making it important to
develop speedy, cost-effective diagnostic tools. This study evaluated recombinant RD1-encoded
antigens of Mycobacterium tuberculosis as tools for serodiagnosis by determining the immunological
reactivity of these proteins against sera from healthy, bacille Calmette–Gue´rin (BCG)-vaccinated and TB-
infected individuals from Kolkata. Rv3872, Rv3875 (ESAT-6) and Rv3878 were able to discriminate
healthy BCG-vaccinated controls from TB patients. Rv3872 showed the highest level of antibody
response in comparison with other antigens, and also showed statistically signiﬁcant differences
between pulmonary (p <0.0001) or extra-pulmonary (p <0.001) TB patients and healthy BCG-vaccinated
individuals. The levels of antibody were measured using 20-mer overlapping peptides spanning the
entire Rv3872 sequence. The immunological reactivity against a mixture of two peptides (P8 and P9)
encompassing amino-acids 57–84 correlated well with that obtained using full-length Rv3872. This result
was explained by the fact that two of the predicted regions of high antigenicity lie within amino-acid
residues 57–85 of Rv3872. The high sensitivity and speciﬁcity of Rv3872, as well as the mixture of two
synthetic overlapping peptides derived from Rv3872, highlight their potential and argue in favour of
their use in serodiagnosis of both pulmonary and extra-pulmonary TB.
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INTRODUCTION
India is classiﬁed, along with the sub-Saharan
African countries, as a country with a high
burden of tuberculosis (TB), accounting for one-
third of the total global burden of this disease.
Estimating the burden of the disease in India,
Gopi et al. [1] reported 3.8 million cases of
bacillary (either sputum ⁄ smear- or culture-posit-
ive) pulmonary TB and 0.8 million cases of extra-
pulmonary TB. Nearly 2 million Indian citizens
develop TB each year, and one in three Indian
citizens carries Mycobacterium tuberculosis.
According to the Indian Ministry of Health and
Family Welfare (http://tbcindia.org), an individ-
ual in India dies every minute from TB, with 75%
being aged between 15 and 54 years. Diagnosis
still depends largely on radiography, sputum
microscopy and bacterial culture, often leading to
delays in treatment. This underscores the need to
develop robust, cost-effective diagnostic tools.
ELISA-based serological tests to detect antibod-
ies to M. tuberculosis components in clinical spec-
imens have the potential of providing inexpensive
and robust tools for diagnosis of active TB under
the conditions encountered commonly in devel-
oping countries such as India. Although a number
of seroantigens have been identiﬁed in recent
years, these are of low sensitivity and speciﬁcity,
because of, in part, the heterogeneity of the
antibody response in TB patients from different
geographical locations [2,3]. Previous studies
have explored the utility of antigens encoded by
a 9.5-kb genomic DNA region of M. tuberculosis,
designated RD1, that is present in all virulent and
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clinical strains of M. tuberculosis and Mycobacteri-
um bovis [4,5], but deleted in all M. bovis bacille
Calmette–Gue´rin (BCG) vaccine strains. The pre-
sent study expressed and evaluated some of the
RD1-encoded antigens of M. tuberculosis, and
evaluated their usefulness as tools for sero-
diagnosis by determining the immunological
reactivity of these proteins with sera from healthy
BCG-vaccinated and TB-infected individuals from
Kolkata.
MATERIALS AND METHODS
Study population
All samples were obtained for routine diagnostic analysis from
patients (who had given informed consent) who were report-
ing to the Bengal Tuberculosis Association for directly
observed short-course therapy, and from healthy BCG-vaccin-
ated individuals, in accordance with the guidelines of the
Institutional Ethics Committee. Healthy donors were individ-
uals without prolonged direct contact with TB patients, who
had been vaccinated with M. bovis BCG >10 years before
reporting to the clinic.
The study population (n = 542) was divided into the
following groups: group 1 (n = 240) comprised patients diag-
nosed with pulmonary TB (as conﬁrmed by examination of
sputum for acid-fast bacilli and ⁄ or culturing) for the ﬁrst time,
with no history of treatment for TB; group 2 (n = 179)
comprised patients with extra-pulmonary TB, as diagnosed
by clinical and radiographical ﬁndings, histopathological
examination and culture of biopsy samples; and group 3
(n = 123) comprised healthy BCG-vaccinated donors. Patients
with both pulmonary and extra-pulmonary manifestations, as
well as those with tuberculous meningitis, were excluded from
the study. Sera were collected from all patients before
chemotherapy was commenced.
Molecular biological procedures
Standard procedures for cloning and analysis of DNA, PCR
and transformation were used [6]. Enzymes used to manipu-
late DNA were from Roche Applied Sciences (Mannheim,
Germany). All constructs made by PCR were sequenced to
verify their integrity. Genomic DNA of M. tuberculosis strain
H37Rv was a generous gift from J. Tyagi (All India Institute of
Medical Sciences, New Delhi, India). The genes encoding
Rv3872, Rv3873, Rv3874 (CFP-10) and Rv3878 were ampliﬁed
from the genomic DNA of M. tuberculosis H37Rv using the
sense and antisense primers shown in Table 1. Rv3875 (ESAT-
6), cloned in pET23b, was obtained from J. Belisle (Colorado
State University, CO, USA) under the TB research materials
contract NIH, NIAID N01-AI40091. Recombinants cloned in
pET28a were grown in Luria–Bertani agar containing kana-
mycin 100 mg ⁄L; ampicillin 100 mg ⁄L was used for the
growth of other recombinants.
Expression of recombinant antigens and puriﬁcation
His-Rv3872. Escherichia coli BL21(DE3) ⁄Rv3872 was grown to
OD600 0.6. Isopropyl-b-D-galactopyranoside (Sigma, St Louis,
MO, USA) was added to a ﬁnal concentration of 0.1 mM, and
growth was continued at 37C with shaking for 2 h. Cells were
lysed with lysozyme at a ﬁnal concentration of 1 mg ⁄mL. The
supernatant was loaded on an Ni2+–nitriloacetic acid (NTA)–
agarose (Qiagen, Hilden, Germany) column equilibrated with
50 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl
and Triton X-100 1% v ⁄v (buffer A). After washing the column
with 100 mM imidazole in buffer A, bound Rv3872 was eluted
with 250 mM imidazole in buffer A.
His-ESAT-6 and His-CFP-10. E. coli BL21(DE3) ⁄ESAT-6 or
E. coli BL21(DE3) ⁄CFP-10 was expressed by induction with
0.1 mM isopropyl-b-D-galactopyranoside at 37C for 4 h. The
cell pellets were lysed with Bugbuster HT (EMD Biosciences,
San Diego, CA, USA), to which was added 0.5 mM EDTA and
100 lM phenylmethylsulphonylﬂuoride. ESAT-6 or CFP-10
was puriﬁed from the cell-free supernatant by chromatogra-
phy on Ni2+–NTA–agarose, as described above. After washing
the column with 50 mM imidazole in buffer A, ESAT-6 was
eluted with 150 mM imidazole in buffer A.
GST-Rv3878. E. coli BL21 ⁄Rv3878 was expressed by induction
with 0.1 mM isopropyl-b-D-galactopyranoside for 2 h at 37C.
Cells were lysed with lysozyme, with Rv3878 being puriﬁed
from the cell-free supernatant by chromatography on gluta-
thione (GST)–Sepharose (GE Healthcare Bio-Sciences, Kwai
Chung, Hong Kong).
Western blotting
Recombinant antigens (20 lg) were separated by SDS-PAGE
and transferred to nitrocellulose membranes (Millipore
India, Bangalore, India). Each membrane was cut into strips
and incubated for 2 h with sera from TB patients or healthy
BCG-vaccinated individuals, diluted 1:200 in phosphate-
buffered saline (PBS) containing Tween-20 0.3% v ⁄v and
bovine serum albumin 0.1% w ⁄v (PBSTA). After washing,
strips were incubated for 1 h at room temperature with
protein A ⁄peroxidase (BD Biosciences, San Diego, CA, USA)
diluted 1:2000 in PBSTA. Detection was by means
Table 1. Primers and vectors used for cloning of RD1-encoded antigens
Antigen Sense primera (5¢ ﬁ 3¢) Antisense primera (5¢ ﬁ 3¢) Cloned between Vector
Rv3872 ATTGGATCCATGGAAAAAATGTCACAT TTAGAATTCCTATTCGGGCGAAGACGCC BamHI and EcoRI pET28a
Rv3873 TTAGGATCCATGCTGTGGCACGCAATG TATGAATTCTCACCAGTCGTCCTCTTC BamHI and EcoRI pET28a
Rv3874 (CFP-10) TTGGATCCCATATGGCAGAGTTGAAGACCG TTGAATTCGGTACCTCAGAAGCCCATTTGCGAG NdeI and EcoRI pET28a
Rv3878 TAGGATCCATGGCTGAACCGTTGGC ATGAATTCCTACAACGTTGTGGTTG BamHI and EcoRI pGEX-2T
aRestriction sites are underlined.
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of chemiluminiscence with Lumiglo reagent (Cell Signa-
ling Technology, Beverly, MA, USA) and exposure to X-ray
ﬁlm.
Synthetic peptides
Eleven 20-mer peptides, overlapping by 12 amino-acids and
covering the entire Rv3872 amino-acid sequence, were
synthesised using solid-phase pin technology (Mimotopes,
Clayton, Victoria, Australia). All peptides were dissolved in
sterile distilled water at a concentration of 2 mg ⁄mL and
were stored frozen at )70C until use. Stock peptide
solutions were diluted to obtain the desired concentration
in PBS.
Antibody detection by ELISA
Microtitre plates were coated with recombinant antigens
(200 ng ⁄well), blocked with PBS containing BSA 1% w ⁄v for
2 h at room temperature, and then washed in PBS contain-
ing Tween-20 0.1% v ⁄v (PBST). Serum (diluted 1:500) was
added to the wells, and the plates were incubated for 1 h at
room temperature, washed with PBST and incubated with
anti-human IgG Fab¢2 peroxidase (Sigma) (1:5000 dilution)
for 1 h at room temperature. Horseradish peroxidase activity
was detected by adding the chromogenic substrate o-phen-
ylene diamine tetrahydrochloride (Sigma) and H2O2. The
reaction was stopped using 1 M H2SO4 and readings were
taken at 490 nm. Each ELISA was repeated on at least three
occasions, with replicates for each sample within individual
ELISAs.
Data analysis
Student’s t-test and ANOVA were used for statistical analyses.
Sensitivity was deﬁned as the ability to detect cases of active
TB. Speciﬁcity was deﬁned as the ability to yield negative
results for the control groups, which were considered to be free
of active TB. For evaluation of antibody responses, cut-off
values were calculated for each antigen as the means of OD490
values plus three SDs obtained with the sera from 123 healthy
BCG-vaccinated donors.
RESULTS
Expression and puriﬁcation of antigens
Rv3872, CFP-10 (Rv3874) and ESAT-6 (Rv3875)
were all expressed as 6x His-tagged proteins in
E. coli and were puriﬁed from cell-free superna-
tants by chromatography on Ni2+–NTA–agarose.
Rv3878 was expressed as a GST-fusion protein
and was puriﬁed by chromatography on GST–
Sepharose. The puriﬁed proteins were analysed
by SDS-PAGE and were detected by probing
with anti-His or anti-GST antibodies (data not
shown). Expression and puriﬁcation results for
Rv3872, Rv3878, CFP-10 and ESAT-6 are shown
in Fig. 1.
Western blot analysis of reactivity of
recombinant proteins against sera from healthy
BCG-vaccinated controls and TB patients
Western blot analysis revealed that recombinant
(r) Rv3872, ESAT-6, CFP-10 and Rv3878 reacted
positively with sera from TB patients, but not
with sera from healthy BCG-vaccinated individ-
uals (representative blots are shown in Fig. 2).
Recognition of RD1-encoded antigens by sera
from healthy and infected subjects
Sera from patients and healthy BCG-vaccinated
individuals were tested against r-Rv3872, r-ESAT-6,
Fig. 1. Expression and puriﬁcation of Mycobacterium tuber-
culosis proteins Rv3872, Rv3878, ESAT-6 and CFP-10.
Coomassie blue-stained SDS gels showing (a) uninduced,
(b) induced and (c) puriﬁed proteins. Protein marker sizes
are indicated on the left side of each gel.
Fig. 2. Western blot of Mycobacterium tuberculosis proteins
using human sera. Puriﬁed recombinant proteins (as
indicated) were separated by SDS-PAGE, transferred
electrophoretically to nitrocellulose membranes, and
probed with human sera. Blots are representative of data
obtained with healthy bacille Calmette–Gue´rin (BCG)-
vaccinated individuals (lanes a and b) and pulmonary TB
patients (lanes c–f).
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r-CFP-10 and r-Rv3878 by ELISA. The sera were
tested simultaneously against tuberculin (puriﬁed
protein derivative; PPD). The data shown in
Table 2 demonstrate that sera from all infected
patientsmounted a statistically signiﬁcant (p <0.01
— <0.0001) antibody response against r-Rv3872,
r-ESAT-6, r-CFP-10 and r-Rv3878 when compared
with that of healthy BCG-vaccinated individuals.
However, sera from TB-infected patients did
not show statistically signiﬁcant differences in
response to PPD when compared with sera from
healthy BCG-vaccinated individuals. When the
immunogenicity of Rv3872 was compared with
that of ESAT-6 and CFP-10, the mean values for
Rv3872 with pulmonary and extra-pulmonary TB
were 1.32 and 0.62, respectively, compared with
0.39 and 0.29, respectively, for ESAT-6, and 0.35
and 0.28, respectively, for CFP-10. The mean
values for Rv3878 with pulmonary and extra-
pulmonary TB were 1.19 and 0.68, respectively
(Table 2). Thus Rv3872 and Rv3878 elicited stron-
ger immunoreactivity than ESAT-6 and CFP-10,
and could discriminate patients with new pul-
monary TB infections from healthy BCG-vaccin-
ated donors (p <0.0001 and p <0.001, respectively,
as tested by ANOVA, for the two proteins). These
values suggested that Rv3872 is a better candidate
for a diagnostic tool than Rv3878 in terms of
distinguishing patients with pulmonary TB from
healthy BCG-vaccinated individuals.
To further analyse the efﬁcacy of each of the
antigens tested, the number of sera reactive
against Rv3872 and Rv3878 were counted (i.e.,
those sera with antibody levels greater than or
equal to the mean OD490 of negative control sera
plus 3 SD). The majority (>90%) of the responders
showed levels of antibody to these antigens
greater than the above cut-off values (Fig. 3).
Sensitivity and speciﬁcity of antigens
With present diagnostic methods, diagnosis of
extra-pulmonary TB is more difﬁcult than that of
pulmonary TB. It would therefore be an advant-
age if a diagnostic tool capable of identifying this
group of patients could be developed. In this
context, Rv3872 and Rv3878 could discriminate
extra-pulmonary TB patients from healthy BCG-
vaccinated individuals with p values of <0.001
and <0.01, respectively (Table 2). For Rv3872, the
sensitivities of detection of pulmonary TB and
extra-pulmonary TB were 92% and 89%, respect-
ively (Table 3). For Rv3878, the values were 88%
and 84% for pulmonary and extra-pulmonary TB,
respectively. For Rv3872 and Rv3878, the specif-
icities were 95% and 91%, respectively. Taken
together, these results suggest that Rv3872 is a
better candidate than Rv3878 for diagnosis of
pulmonary and extra-pulmonary TB infections.
Immunoreactivity against synthetic peptides
covering the Rv3872 sequence
Rv3872 was chosen in preference to Rv3878 for a
detailed investigation into the potential serodiag-
nostic use of immunogenic peptides derived from
its sequence. Overlapping peptides (P1–P11,
Table 4) covering the entire Rv3872 sequence
were synthesised in order to identify B-cell
epitopes. These peptides were used to test for
reactivity against the sera of patients with both
categories of TB described above. Two overlap-
ping peptides (P8 and P9) were identiﬁed as
important antigenic epitopes of Rv3872. These
peptides reacted strongly with the sera obtained
from both categories of patients (Fig. 4). There
was a four- to ﬁve-fold increase in the mean
values, compared with normal individuals, when
P8 or P9 were used individually with pulmonary
TB patients (Fig. 4). With use of the mixture of P8
and P9, the mean value increased almost eight-
fold (p <0.0001) (Table 2).
The pooled P8 and P9 peptides, like the full-
length protein, showed a signiﬁcantly higher
response against pulmonary TB infections than
against extra-pulmonary TB infections (Fig. 4,
Table 2. Summary of antibody lev-
els obtained by ELISA against RD1-
encoded antigens of Mycobacterium
tuberculosis and tuberculin (PPD)
Category PPD Rv3872 ESAT-6 CFP-10 Rv3878 P8 + P9
Group 1 0.30 ± 0.05a 1.32 ± 0.09b 0.39 ± 0.03c 0.35 ± 0.02c 1.19 ± 0.07c 1.47 ± 0.06b
Group 2 0.25 ± 0.08a 0.62 ± 0.02c 0.29 ± 0.01d 0.28 ± 0.02d 0.68 ± 0.03d 0.71 ± 0.020c
Group 3 0.22 ± 0.05 0.21 ± 0.02 0.14 ± 0.01 0.12 ± 0.02 0.41 ± 0.03 0.25 ± 0.01
Groups 1, 2 and 3 represent pulmonary tuberculosis (TB), extra-pulmonary TB, and healthy individuals vaccinated
with bacille Calmette–Gue´rin, respectively. Data are represented as means ± SD of absorbance values at 490 nm.
Statistical signiﬁcance was determined by ANOVA.
aNot signiﬁcant; bp <0.0001; cp <0.001; dp <0.01 (p values are given with respect to group 3).
P8 + P9 is a mixture of peptides P8 and P9 derived from Rv3872.
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Table 2). The speciﬁcity of the peptide cocktail
was 100% and the sensitivities were 94% and
90%, respectively, for pulmonary and extra-pul-
monary TB (Table 3). As with the full-length
protein, <10% of sera from BCG-vaccinated
healthy individuals showed an antibody response
above the cut-off value (Fig. 3). These pep-
tides showed a stronger immunoreactivity for
patients with pulmonary TB infections than for
BCG-vaccinated healthy individuals (Fig. 4)
(p <0.0001).
Rv3872 was scanned to identify regions of high
antigenic index using the online antigenic peptide
prediction software available at http://imm
unax.dfci.harvard.edu, following the method of
Kolaskar and Tougaonkar [7]. Three antigenic
sites, encompassing amino-acids 21–52, 57–65 and
68–85, respectively, were predicted. Peptides P8
Fig. 3. Antibody responses to re-
combinant (r)-Rv3872, r-Rv 3878,
r-ESAT-6, r-CFP10 and a mixture of
peptides (P8 and P9) derived from
Rv3872. Levels of antibody response
in pulmonary (group 1) and extra-
pulmonary (group 2) tuberculosis
patients, as well as healthy indi-
viduals vaccinated with bacille
Calmette–Gue´rin (group 3) were
measured by ELISA. Each point
represents one serum sample. The
horizontal bar in each panel repre-
sents the cut-off value determined as
mean absorbance plus 3 SD by use
of negative control sera.
Table 3. Sensitivity and speciﬁcity of recombinant Rv3872, recombinant Rv3878 and the peptide cocktail (P8 and P9)
derived from Rv3872
Category Number of individuals
Number of positive individuals Sensitivity (%) Speciﬁcity (%)
Rv3872 Rv3878 P8 + P9 Rv3872 Rv3878 P8 + P9 Rv3872 Rv3878 P8 + P9
Group 1 240 222 208 226 92.5 88 94.2
Group 2 179 159 148 161 88.8 84 90
Group 3 123 6 12 0 95 91 100
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and P9 encompass amino-acid residues 57–76 and
65–84, respectively, thereby explaining the obser-
vation that these peptides of high predicted
antigenicity elicit strong immunoreactivity when
tested by ELISA.
DISCUSSION
Considering that India accounts for one-third of
the global TB burden, early cost-effective diagno-
sis is a priority. The present study evaluated the
serological response to a panel of recombinant
RD1-encoded antigens of M. tuberculosis. PPD
failed to discriminate TB patients from healthy
BCG-vaccinated individuals, thereby corrobor-
ating earlier observations [8,9]. The promise of
an antigen as a serodiagnostic tool depends not
only on the number of antibody responders
among TB patients, but also on the level of
response obtained with an antigen. Compared
with CFP-10 and ESAT-6, the differences in mean
absorbance values among TB patients and healthy
BCG-vaccinated individuals were much higher
for Rv3872 and Rv3878 (Table 2). However,
Rv3873 gave a positive reaction with sera from
healthy BCG-vaccinated individuals as well as
with sera from TB-infected patients (unpublished
results), and was therefore excluded from further
study.
The present ﬁndings contradict those of earlier
workers [10], who reported that only 3–7% of TB
patients responded to RD1 region proteins, inclu-
ding Rv3872 and Rv3878, although all RD1
antigens elicited a high antibody response in
guinea-pigs infected with M. tuberculosis. This is
not surprising, since the serological response to a
Table 4. Amino-acid sequences of synthetic peptides
derived from the Rv3872 sequence
Peptide no.a Sequence
P1 (1–20) MEKMSHDPIAADIGTQVSDN
P2 (9–28) IAADIGTQVSDNALHGVTAG
P3 (17–36) VSDNALHGVTAGSTALTSVT
P4 (25–44) VTAGSTALTSVTGLVPAGAD
P5 (33–52) TSVTGLVPAGADEVSAQAAT
P6 (41–60) AGADEVSAQAATAFTSEGIQ
P7 (49–68) QAATAFTSEGIQLLASNASA
P8 (57–76) EGIQLLASNASAQDQLHRAG
P9 (65–84) NASAQDQLHRAGEAVQDVAR
P10 (73–92) HRAGEAVQDVARTYSQIDDG
P11 (81–99) DVARTYSQIDDGAAGVFAE
aNumbers in parentheses correspond to the corresponding amino-acid residues of
Rv32872.
(a)
(c)
(b)
(d)
Fig. 4. Antibody response of tuberculosis (TB) patients and healthy individuals vaccinated with bacille Calmette–Gue´rin
(BCG) to synthetic peptides. (a, c) Serum reactivity to individual synthetic peptides or a cocktail of P8 and P9 with sera
from extra-pulmonary (a) and pulmonary (c) TB patients. (b) Serum reactivity to the peptides with sera from pulmonary TB
patients and healthy, BCG-vaccinated individuals. (d) Serum reactivity to peptide cocktail (P8 and P9) with sera from
pulmonary (group 1) and extra-pulmonary (group 2) TB patients, as well as from healthy, BCG-vaccinated individuals
(group 3). Responses to all the peptides were plotted as absorbance at 490 nm (means ± SD). For (b), the differences in
response between normal and patient sera were not signiﬁcant for peptides P1–P6 and P11 (p >0.05). For (d), comparison
was made with respect to sera from healthy BCG-vaccinated individuals (group 3). ***p <0.0001; **p <0.001; *p <0.01.
Statistical analyses were performed using ANOVA for (c) and Student’s t-test for (d).
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speciﬁc antigen often depends on the geograph-
ical location and ethnic background of the
population being studied. For example, large
variations in sensitivity have been reported using
the same antigens against sera from TB patients
living in Denmark and those living in Uganda
[11]. In addition, Weldingh et al. [11] have sug-
gested that the magnitude of the antibody
response depends on the stage of disease at
which patients from areas of high and low
endemicity are admitted to hospital.
Genetic as well as environmental factors also
inﬂuence the antibody response. The diverse
antibody response to M. tuberculosis is governed
by HLA types. Arend et al. [12] reported that
interferon-c production by peripheral blood
mononuclear cells of TB patients was signiﬁcantly
higher in the presence of HLA-DR15, which is a
major subtype of DR2. It is therefore not surpris-
ing that, contrary to the results of studies in
western countries, Rv3872 appears to be a prom-
ising antigen for developing serological diagnosis
kits for detecting TB in the context of an Indian
population residing in an endemic area.
In conclusion, the data presented in this study
highlight the potential of the recombinant RD1-
encoded antigen Rv3872, as well as the peptide
cocktail derived from this protein, for serodiag-
nosis of both pulmonary and extra-pulmonary
TB. The promising results obtained with the
peptide cocktail argue in favour of its inclusion
in serodiagnostic ELISA kits for the detection of
TB. Additional efforts are now being made to
develop serological approaches for detection of
smear-negative infections using the peptides
derived from Rv3872. The practical utility of
using such a peptide cocktail for differentiating
fresh infections from relapsed infections is an
additional aspect that deserves further investiga-
tion.
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